Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Itacitinib - Incyte Corporation

Next Previous
X
Search
Drug Profile

Itacitinib - Incyte Corporation

Alternative Names: IBI-377; INCB-039110; INCB-039110-adipate; INCB-39110; Itacitinib-adipate

Latest Information Update: 28 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP); AstraZeneca; H. Lee Moffitt Cancer Center and Research Institute; Incyte Corporation; Innovent Biologics; National Cancer Institute (USA); University of Utah
  • Class Acetonitriles; Anti-inflammatories; Antianaemics; Antibronchitics; Antineoplastics; Antipsoriatics; Antirheumatics; Azetidines; Fluorocarbons; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cytokine release syndrome; Diffuse large B cell lymphoma; Diffuse scleroderma; Haemophagocytic lymphohistiocytosis; Hodgkin's disease; Immunological disorders; Myelofibrosis; Non-small cell lung cancer
  • Phase I/II Bronchiolitis obliterans; Haematological malignancies; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Graft-versus-host disease
  • No development reported Aplastic anaemia; Liver cancer; Malignant melanoma; Soft tissue sarcoma; T-cell prolymphocytic leukaemia
  • Discontinued Pancreatic cancer; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Graft-versus-host-disease(Prevention) in USA (PO)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in T-cell-prolymphocytic-leukaemia(Combination therapy, First-line therapy) in USA (PO)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in T-cell-prolymphocytic-leukaemia(Combination therapy, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top